SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-005722
Filing Date
2023-03-01
Accepted
2023-03-01 06:37:51
Documents
20
Period of Report
2023-03-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20230301.htm   iXBRL 8-K 37006
2 EX-99.1 pressrelease-4q22financi.htm EX-99.1 21819
6 pressrelease-4q22financi001.jpg GRAPHIC 246024
7 pressrelease-4q22financi002.jpg GRAPHIC 245147
8 pressrelease-4q22financi003.jpg GRAPHIC 287477
9 pressrelease-4q22financi004.jpg GRAPHIC 220704
10 pressrelease-4q22financi005.jpg GRAPHIC 264116
11 pressrelease-4q22financi006.jpg GRAPHIC 26670
12 pressrelease-4q22financi007.jpg GRAPHIC 140677
  Complete submission text file 0001628280-23-005722.txt   2181068

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20230301.xsd EX-101.SCH 1920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20230301_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20230301_pre.xml EX-101.PRE 13058
14 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20230301_htm.xml XML 11842
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 23689628
SIC: 2834 Pharmaceutical Preparations